14Feb
27Sep
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
Corbus Pharmaceuticals Holdings, Inc., an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors. Read more >>
08Dec
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Unit.
01Jul
Corbus Pharmaceuticals Expands Pipeline with Two New mAbs
Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer. Read more >>
02Jun
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ. High potency anti-αvβ8 mAb licensed from University of California San Francisco andanti-αvβ6/αvβ8 mAb licensed from Panorama Research Inc. Both mAbs expected to start Phase 1 testing in 2022. Capital and resources in place to advance multiple programs into clinical development. Read more >>
26May
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021. Read more >>
22Jan
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New York Academy of Sciences' webinar on January 27, 2021 on the endocannabinoid system as a target for therapeutic agents. Read more >>
13Nov
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST. Read more >>
10Nov
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the RESOLVE-1 Phase 3 study of lenabasum for the treatment of systemic sclerosis. Read more >>
24Oct